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Abstract . •
Symptomatic HIV infection was first diagnosed in an Irish child in 1985. A prospective study
was initiated to determine the vertical transmission rate (VTR) of HIV and the average age of
infant seroreversion and to monitor clinical, immunologic and virologic evidence for HIV infection
in seroreverters. Ninety three HIV positive infants have been prospectively identified since 1985.
The predominant underlying maternal risk factor for HIV infection is intravenous drug use (IVDU)
(96 per cent). Of 93 infants, median gestational age was 40 weeks and median birth weight 3125
grams. Ninety-four per cent of infants were bottle fed. Currently 72 (77 per cent) infants are
uninfected, 12 (13 per cent) are infected, 4 (4.5 per cent) are indeterminate and 5 (5.5 per cent)
have been lost to follow up. The intermediate estimate of vertical transmission rate (VTR) is 14.3
per cent. The median age at documented seroreversion was 12 months. There are no significant
differences between infected and non-infected children in male\female ratio, gestational age, mode
of delivery or birth weight. Strategies to reduce the transmission of HIV among drug users in
combination with routine antenatal screening and antiretroviral prophylaxis of vertical
transmission are all measures which can reduce HIV infection in our children.
Introduction
Perinatal or vertical transmission (VT) of human
immunodeficiency virus (HIV) was first reported in 1982'.
Three years later, in 1985, the first Irish child with
symptomatic HIV infection was diagnosed. As of March
1997, 128 HIV positive children have been identified. HIV
infection has been confirmed in 37, of whom 19 have been
diagnosed with acquired immunodeficiency syndrome
(AIDS). Thirty-two (86 per cent) of these children have
acquired HIV as a result of maternal transmission during
the pregnant or perinatal period. This study was initiated
in 1985. The data presented is based only on the cohort of
infants followed prospectively from birth and therefore
does not include all HIV infected children in the Republic
of Ireland.
Methods
Enrolment and follow up
Notice was given from adult HIV services and from
each of the 3 Dublin maternity hospitals of expectant
HIV infected women. Epidemiological information was
collected for these mothers and infants were referred to
the Paediatric HIV service. Evaluations were scheduled
at birth, 3, 6, 9, 12, 15 & 18 months of age according
to HIV status and 3 monthly or yearly thereafter.
Clinical evaluation and, where possible, immunologic
and virologic evaluation were carried out at each time
point.
Correspondence and proofs to:
Clare Nourse,
Children's Research Centre,
Our Lady's Hospital for Sick Children,
Crumlin, Dublin 12.
HIV testing
HIV testing was carried out at the virus reference
laboratory, University College Dublin using testing
methods available at the time. HIV antibody was detected
using 2 tests; an ELISA (Wellcozyme, Wellcome
Diagnostics) and either an alternative ELISA or a particle
agglutination assay (Serodia HIV, Fujirebio Inc. Tokyo).
Antibody is currently detected using an antigen sandwich
enzyme immune assay (Murex HIV 1+2, Murex
Diagnostics, Dartford, Britain and a particle agglutination
assay (Serodia HIV, Fujirebio Inc, Tokyo). Confirmation
assay was performed initially with HIV-1 Western blot
assay (Cambridge Biotech) and is now performed with
Inno-Lia confirmation assay (Innogenetics, Zwijndrecht,
Belgium).
p24 Antigen is detected using Murex HIV antigen Mab
and Murex HIV antigen ICD (Murex Diagnostics,
Dartford, UK) (Previously performed by Abbott EIA
assay). HIV DNA from the pol region of the genome is
amplified from DNA extracted from peripheral blood
mononuclear cells in a nested PCR assay similar to that
described by Ou et al 19882. HIV RNA levels in plasma
are quantified using the HIV monitor assay (Roche
Diagnostics). Virus cultures were performed on a subset
of infants at the Department of Virology, St. Thomas's
Hospital, London.
In accordance with current recommendations3, children
were considered infected if they fulfilled 1 of the following
criteria:
• HIV antibody positive > 18 months of age
• HIV antibody positive plus other virologic evidence of
infection (p24 antigen, PCR or culture) documented on
at least 2 occasions separated by a 2 week interval and
< 18 months of age
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Figure 1 - Prospectively identified infants born to HIV infected
mothers and infant status by year of birth (1985-1996).
• CDC AIDS case definition criteria
Children were considered uninfected if they were > 9
months of age, antibody negative, and had no clinical
evidence of infection. All other children are considered
to be of indeterminate status4.
The vertical transmission rate (VTR) was calculated
as recommended by the Ghent conference on mother to
child transmission of HIV infection4. The numerator is
the number of infected children and the denominator the
number infected plus the number uninfected. An
intermediate estimate of VTR assumes that indeterminate
cases provide no information on HIV infection status. A
lower estimate of VTR assumes that indeterminate cases
are not infected. The age at serorevarsion is defined as
the midpoint between age at the last positive antibody test
and age at the first negative test.
Results
Ninety-three infants born to 71 HIV infected women
were identified between August 1985 and March 1997
(Figure 1). Most women had other children with parity
ranging up to 6 at the time of delivery.
Maternal Characteristics "
The median age of mothers at delivery was 24.8 (range
20-36.3) yr. The risk factors underlying infection in the
mothers were intravenous drug use (IVDU) by the woman
Unknown (1%)
HST (3%)
IVDU (77.5%)
HST with IVDU (18.5%)
Figure 2 - Maternal risk factors for HIV infection.
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TABLE I
Mode of delivery and infection status of 71 mothers and 93
infants (August 1985 - March 1997)
herself (n=72; 77.5 per cent), heterosexual contact with
an IV drug user (n=17; 18.5 per cent) or heterosexual
contact with a partner not identified as being an IV drug
user (n=3; 3.2 per cent). In one case risk factors were
unknown (Figures 2 and 3).
Table I illustrates the mode of delivery and infection
status of mothers and infants. As of March 1997, 29 (31
per cent) of mothers have died of HIV related causes; 29
are living with HIV infection and 13 have been lost to
follow up.
Infant Characteristics
Forty-eight infants were male and 45 female. Ninety
(94 per cent) infants were bottle fed. Median gestational
age was 40 weeks (range 33-44 weeks) and median birth
weight was 3125 g (range 1705-4250 g) (Table II). Details
of the infection status of infants are included in Table I.
Four infants are of indeterminate staus and 5 infants have
been lost to follow up.
Eighty-four infants have been tested at >15 months.
Of these, 72 are HIV negative and 12 are HIV positive
(Fig. 1.). Thus the intermediate estimate of VTR for this
group is 14-.3 percent (95 percent C.I. 7.6-23.6 percent).
Of all 93 infants the lower estimate of VTR is 12.9 per
infected infants
uninfected mlanis
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Figure 3 - Maternal risk factors for HIV infection by year of
birth of infant (1985-1996).
Mode of Delivery
Vaginal
Instrumented Vaginal
Caesarean Section
Not recorded
Maternal Status at Delivery
Asymptomatic
Symptomatic
Not recorded
Current Infection Status of Infants
Uninfected
Infected
Indeterminate
Lost to follow up
n(%)
77 (82 8)
6(6.5)
9 (9.7)
1 (1.0)
64 (68.8)
13(14.0)
16(17.2)
72 (77)
12(13)
4 (4.5)
5(5.5)
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TABLE II
Comparison of characteristics between infected and
non-infected children
Seronegative
(n=72 )
Infected
(n=l2)
Male: Female ratio
Proportion interventional delivery
•Gestational Age at birth (weeks)
*Birth Weight (g)
•median values given
1.5:1 (43:29)
14/72(19%)
40 [33-44]
3076(1705-4250]
1:1.4(5:7)
1/12(0.8%)
39 [37-41]
3450 [2892-3860]
cent (95 per cent C.I. 6.8-21.5 per cent). The median age
at diagnosis of infected infants was 11 months (1 month
to 2 yr).
Since the introduction of prenatal, intrapartum and
postnatal (infant) administration of zidovudine
prophylaxis in 1995, none of the 6 infants born to HIV
infected mothers has evidence of infection to date (one
born in 1997 not included in Figure 1).
The median age at documented seroreversion in 72
seroreverters was 12 months. The earliest documented
seroreversion was at 4 months but because of poor
compliance with protocol, seroreversion was documented
as late as 34 months in 1 child. No seroreverting child
had a documented positive test at >15 months of age. No
positive tests were documented after seroreversion during
a median follow-up period of 22.5 months (range 0-99.5
months). Thirteen failed to return for further testing once
seroreversion was documented. None of these children
have any HIV related illness.
Of 84 children with a definitive outcome (12 infected
and 72 uninfected), the current median age of infected
children is 66 months and of seroreverters is 75 months.
There are no significant differences between infected and
non-infected children in male/female ratio, gestational age,
mode of delivery or birth weight (Table II)
Discussion
From August 1985 to March 1997, 93 infants born to
71 HIV infected women have been prospectively identified
(Fig 1). This number most likely under-represents the true
number of infants born to HIV infected mothers as, in the
absence of universal antenatal screening, all HIV infected
mothers are not identified. Some women fail to disclose
their status. Others are not aware of their status, and
importantly, many do not perceive themselves to be at risk
of infection. Most of the HIV infected children attending
the paediatric HIV service have not been recognised to be
at risk of infection at the time of birth (Nourse et al,
Paediatric HIV infection in the Republic of Ireland and
need for antenatal screening, in press).
It appears from this study that the number of
prospectively identified infants born to HIV infected
mothers in the Dublin area is declining. However updated
figures for 1997 (9 women in total) and 1998 (4 women
in the first quarter) suggest that this trend in now being
reversed.
Recently published results of an unlinked anonymous
survey of HIV infection among antenatal women estimate
the overall national prevalence of HIV infection in
childbearing women at 0.016 per cent, (1/6,427) with an
estimate of at least 0.037 per cent, (1/2,675) in the Dublin
area (Surveillance Subcommittee of the National AIDS
Strategy Committee, June 18, 1997) Early identification
of HIV infected pregnant women is critical in order to
facilitate strategies to halt mother to infant transmission
of HIV. Antenatal testing can be voluntary, mandatory,
targeted or universal and is a controversial issue. Decisions
to test are made on an individual country basis and to date
have been largely governed by prevalence rates in the
population considered. Now that effective strategies for
prevention of VT are available, where resources permit,
unlinked routine antenatal testing should be introduced
in any endemic areas of HIV infection. It is interesting to
note that despite being aware of their status and the
resulting risks of vertical transmission, 10 infected women
in this report proceeded to have further children.
The study reveals the importance of drug use as a risk
factor for HIV infection in Irish women. In 96 per cent of
cases, infection in the mother was either directly or
indirectly linked to intravenous drug use. However, the
number of new cases with IVDU as a risk factor has shown
a downward trend over the last 10 yr while the number of
new cases with heterosexual transmission (HST) as a risk
factor has remained constant. It would appear that HST is
becoming a relatively more important risk factor for HIV
infection in women in the Republic of Ireland (Figure 3).
In the cohort studied, vaginal deliveries were usual.
Evidence has suggested that delivery by Caesarean section
may result in less vertical transmission of HIVSft but most
centres are awaiting the results of further prospective
studies before adopting a change in routine policy for
delivery of the HIV positive mother.
Although 69 per cent of mothers were asymptomatic
at the time of delivery, in this pre-triple therapy era, 29
(31 per cent) of the 71 mothers have since died from HIV
related illness. This illustrates the enormous effect of HIV
infection on a family, including those members uninfected
by the virus.
The majority of women had full term deliveries and
most infants were of average birth weight. HIV infection
during pregnancy does not appear to have adversely
affected the fetus. Findings from studies in the developed
world report generally good outcomes7, with only
occasional reports of low birth weight" and premature
delivery9. In this study, only 3 women breast fed their
infant, the last doing so in 1991. Due to the documented
transmission of HIV from breast milk to infants, current
WHO recommendations are that mothers in countries
where safe alternatives to breast milk are readily available
should not breast feed their babies10.
Whether based on all available information or
restricting it only to those infants greater than 15 months
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when last tested, the VTR of HIV infection in the Republic
of Ireland lies around 12-15% with confidence intervals
of 6-23% and is consistent with rates reported from other
European studies"13.
We found no significant differences between infected
and non-infected children with regard to potential risk
factors for vertical transmission. However our relatively
small numbers would preclude such a finding. Importantly
there have been no subsequent diagnoses of HIV infection
among seroreverting children.
Conclusion
Intravenous drug use is the main risk factor underlying
HIV infection in this group. Increasingly we are witnessing
the result of heterosexual spread of HIV infection to
partners of drug users who have themselves never abused
drugs. The impact of HIV infection on children (infected
or uninfected) is huge and is exemplified by the significant
number of mothers (31 per cent) who have died.
The VTR of 12-15 per cent is similar to that of other
European studies and is lower than that reported from the
U.S. and Africa. We are optimistic that antiretroviral
prophylaxis will further reduce this rate. Current anecdotal
reports of even more successful intervention when
Caesarean section and antiretroviral therapy are combined
leads one to hope that vertically transmitted HIV infection
will be a completely preventable disease. In this study,
lack of evidence of HIV infection among clinically well
seroreverters followed for up to 99 months post
seroreversion is reassuring.
As the greater number of optionsytivailable to prevent
VT of HIV can have an enormous impact on childhood
HIV infection, the time for routine antenatal testing for
HIV infection is now here.
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